Projectes

Codi

101166227

Investigador/a principal

Begoña Nafria Escalera

Rol

Participant

Any d'inici

2025

Any de finalització

2030

Import total

258950€

Objectius

Clinical studies often lack diverse participants, causing knowledge gaps in disease research and treatment effectiveness. Marginalized groups face barriers like mistrust and geographic limitations. REaDI aims to address these issues by integrating stakeholders, providing tools and training for inclusive recruitment, and developing a digital platform. With 40 organizations from 14 EU countries, REaDI will test its solutions through pilot cases to enhance clinical trial inclusivity and sustainability.

Codi

101165912

Investigador/a principal

Maria del Carmen Fons Estupiña

Rol

Participant

Any d'inici

2025

Any de finalització

2029

Objectius

European Commission_Carme Fons

Codi

RYC2023-043724-I

Investigador/a principal

Patricia Garcia Cañadilla

Rol

Individual

Any d'inici

2025

Any de finalització

2029

Import total

251800€

Objectius

MINISTERIO DE CIENCIA E INNOVACIÓN_Patricia Cañadilla

Codi

FI24/00206

Investigador/a principal

Carmen Muñoz Almagro

Rol

Individual

Any d'inici

2025

Any de finalització

2028

Import total

89900€

Objectius

ISCIII_Carmen Muñoz

Codi

PI24/00803

Investigador/a principal

Eulalia Baselga Torres, Ruben Berrueco Moreno

Rol

Individual

Any d'inici

2025

Any de finalització

2027

Import total

288750€

Objectius

ISCIII_Eulàlia Baselga

Codi

101172624

Investigador/a principal

Salvador Maneu Marcos

Rol

Participant

Any d'inici

2025

Any de finalització

2027

Import total

263562€

Objectius

EUROPEAN COMMISSION_Salvador Maneu

Codi

PI24/00804

Investigador/a principal

Jaume Mora Graupera, Sara Sánchez Molina

Rol

Individual

Any d'inici

2025

Any de finalització

2027

Import total

145000€

Objectius

Evidence support the existence of a CD133 positive cancer stem cell (CSC) subpopulation in Ewing Sarcoma (EwS), a unique human only and highly aggressive bone and soft tissue malignancy characterized by EWSR1-FLI1 translocation. Attempts to augment therapeutic effectiveness in tumors with documented cellular hierarchy should ideally include strategies that target not only rapidly dividing bulk tumor cells but CSC as well. Our previous work has provided supportive data to propose enhancer disruption as an alternative to effectively disable EWSR1-FLI1 activity. We have demonstrated that Pevonedistat regulates the EWSR-FLI1 cofactor RING1B, while synergizing with PARP inhibitors. Given the fact that all cells in EwS, including CSC, are dependent on the activity of the fusion oncogene, we propose to guide our epigenetic strategy to the CSC compartment. We hereby propose to characterize the CSC compartment in PDX models and target the CD133 subpopulation with combinations of enhancer disruptors and PARP inhibitors. To better reproduce the clinical scenario in patients, we propose to test CSC target therapy at the time when the highly proliferative component of the tumor has receded by standard chemotherapy, i.e. the clinical time defined as non-progressive refractory disease. To that end, the CSC compartment will be characterized in our Irinotecan-refractory EwS xenograft models, where epigenetic enhancer disruptive therapy will be tested. Here, we aim to capture all the preclinical in vivo data necessary to inform the design of a clinical trial where epigenetic targeted therapy based on enhancer disruption might offer the best chances to translate into improved patient outcomes.

Codi

PI24/00424

Investigador/a principal

Alessandra Magnani

Rol

Individual

Any d'inici

2025

Any de finalització

2027

Import total

190000€

Objectius

ISCIII_Alessandra Magnani

Codi

PI24/00473

Investigador/a principal

Daniel Natera de Benito

Rol

Individual

Any d'inici

2025

Any de finalització

2027

Import total

152500€

Objectius

ISCIII_Daniel Natera

Codi

PI24/00467

Investigador/a principal

Laia Alsina Manrique de Lara

Rol

Individual

Any d'inici

2025

Any de finalització

2027

Import total

215000€

Objectius

ISCIII_Laia Alsina